AudioEye (AEYE) Q3 2026 Earnings Call Transcript

AudioEye reported Q3 2026 revenue of $11 million, up 7%, and its first GAAP net income of $1 million, versus a $600,000 loss a year earlier. Adjusted EBITDA rose 58% to $3.9 million, adjusted gross margin reached 88%, and ARR grew 12% to $43.3 million; management raised full-year adjusted EBITDA guidance to $13.4 million–$13.6 million, about 50% year-over-year growth. The company also authorized a $15 million stock repurchase program and launched two AI-driven accessibility products, while noting that customer feedback and monetization opportunities for the new products are still early.

Analysis

The key underwriting question is whether AI is creating a durable revenue engine or mainly improving near-term margins. Current profitability appears more directly supported by cost discipline and automation than by demonstrated monetization of the new products: customer growth trails ARR growth, while management has not yet quantified product attach rates or incremental revenue per customer. That leaves meaningful upside if upsells emerge, but makes extrapolating current EBITDA growth into a steady-state multiple risky.

Regulation and private litigation can support demand, but the timing is uneven: Hawaii’s implementation depends on rules and has a multi-year compliance window, while European enforcement is another potential catalyst rather than booked revenue. Treat the company’s accessibility-performance and legal-protection claims as company-reported until validated by customer adoption and renewal data. The claimed proprietary data advantage may help, but does not prevent larger software platforms or AI tooling vendors from bundling basic accessibility checks.

Near term, buyback authorization may support the stock, but cash generation, debt constraints, actual repurchase pace, and share liquidity matter more than the headline authorization. The counter-consensus risk is that investors capitalize margin expansion as structural while underweighting modest top-line growth and unproven product contribution. Over 1–3 months, watch ARR, net customer additions, and new-product attach/upsell evidence; over 6–18 months, regulatory enforcement and sustained cash conversion determine whether the thesis compounds.

Key Decisions for Investors

• Do not chase a post-earnings move on the margin story alone. Consider a small, staged long in AEYE only if valuation and trading liquidity are acceptable; add on evidence that ARR growth holds near current levels and the new products generate paid expansion, not just positive beta feedback.
• Use the next 1–2 reports as the catalyst test: track enterprise ARR, partner ARR, customer additions, product attach rates, and renewal/upsell trends. Failure of ARR growth to remain around low double digits, or no measurable monetization from Agentic Audits and SDK MCP, would weaken the long thesis.
• Verify reported free-cash-flow reconciliation, capitalized software spending, cash needs, credit-facility terms, and actual buyback execution before treating the authorization as a valuation floor. A slower repurchase pace or cash conversion below adjusted EBITDA expectations would increase balance-sheet and dilution risk.
• Falsification over 6–18 months: gross-margin gains reverse, operating costs rise faster than revenue, or regulatory implementation/enforcement fails to translate into paid demand. Conversely, repeatable product attach and improving ARR growth would support a more durable growth-and-margin thesis.